Enhertu approved in China for patients with previously treated HER2-positive advanced or metastatic gastric cancer
Approval based on DESTINY-Gastric06 results which showed Enhertu demonstrated clinically meaningful efficacy in this setting. Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years.AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has received conditional approval in China as a monotherapy for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received two or more prior treatment regimens. The conditional approval by the National Medical